Back to Results

Citius Pharmaceuticals Inc (CTXR)

Citius Pharmaceuticals, Inc. is a biopharmaceutical company listed on NASDAQ under the ticker CTXR. The company develops and seeks to commercialize products focused on critical care and related medical needs. Its approved product, LYMPHIR, is a targeted immunotherapy used in cutaneous T-cell lymphoma. Citius also has several late-stage development programs, including Mino-Lok for catheter-related bloodstream infections, Halo-Lido for hemorrhoid symptom relief, and NoveCite for acute respiratory distress syndrome. Founded in 2007, the company is headquartered in Cranford, New Jersey.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-CTXR
$0.83
39.0% Upside
Undervalued
$4
568.9% Upside
Bargain
Weak
0.0%
December 17, 2026
0.2x
2.3x
16.422 M
15.882 M
22.2%
98.2%
-13.0
75.3%
Valuation • Fair Value

Citius Pharmaceuticals Inc (NASDAQ-CTXR) Fair Value by Valuation Model

Review the available estimates for Citius Pharmaceuticals Inc (NASDAQ-CTXR), including Comps Fair Value.

Primary Valuation Read

Fair Value

$0.83

Estimated upside of 39.0% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$0.83

Comparable-company valuation reference.

Analyst Price Target

$4

Analysts imply upside of 568.9%.

How to read these valuation models

Use the 4 available valuation references for Citius Pharmaceuticals Inc (NASDAQ-CTXR) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Citius Pharmaceuticals Inc (NASDAQ-CTXR)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

7.105 M

Current operating scale indicator.

Revenue Forecast

10.051 M

Forward revenue estimate.

EBITDA

0 K

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Citius Pharmaceuticals Inc (NASDAQ-CTXR) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Citius Pharmaceuticals Inc (NASDAQ-CTXR)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

3

Weak quality score that deserves closer review.

Altman Z-Score

-13.0

Lower score that deserves closer risk review.

FCF / Net Income

75.3%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Citius Pharmaceuticals Inc (NASDAQ-CTXR). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Citius Pharmaceuticals Inc (NASDAQ-CTXR)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

December 17, 2026

Days to Earnings

86

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Citius Pharmaceuticals Inc (NASDAQ-CTXR), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Citius Pharmaceuticals Inc (NASDAQ-CTXR) Stock Forecast & Technical Outlook

Review Citius Pharmaceuticals Inc (NASDAQ-CTXR) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Citius Pharmaceuticals Inc (NASDAQ-CTXR) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Citius Pharmaceuticals Inc (NASDAQ-CTXR) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Buy

The daily technical read for Citius Pharmaceuticals Inc (NASDAQ-CTXR) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Citius Pharmaceuticals Inc (NASDAQ-CTXR) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Citius Pharmaceuticals Inc (NASDAQ-CTXR) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Citius Pharmaceuticals Inc (NASDAQ-CTXR)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Citius Pharmaceuticals Inc (NASDAQ-CTXR) has a Strong Buy consensus, with 1 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 0
Sell 0
FAQ • Fast Investor Answers

Citius Pharmaceuticals Inc (NASDAQ-CTXR) Stock FAQ

Data-supported answers about Citius Pharmaceuticals Inc (NASDAQ-CTXR), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$0.83
Estimated upside 39.0%
Valuation Rating
Undervalued
Estimated upside of 39.0%
Analyst Target
$4
Implied upside 568.9%
Financial Health
Weak
Current financial-health read

The current fair value estimate for Citius Pharmaceuticals Inc (NASDAQ-CTXR) is $0.83. This implies an estimated upside of 39.0% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 39.0% versus the current market price.

The available analyst price target for Citius Pharmaceuticals Inc (NASDAQ-CTXR) is $4. The analyst target implies estimated upside of 568.9%.

The current financial health read for Citius Pharmaceuticals Inc (NASDAQ-CTXR) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Citius Pharmaceuticals Inc (NASDAQ-CTXR) is December 17, 2026.

The latest available data indicates no current dividend yield for Citius Pharmaceuticals Inc (NASDAQ-CTXR).

The current market capitalization listed for Citius Pharmaceuticals Inc is 16.422 M.

The current enterprise value listed for Citius Pharmaceuticals Inc is 15.882 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Citius Pharmaceuticals Inc is NASDAQ-CTXR, and the stock is listed on NASDAQ.

Citius Pharmaceuticals Inc (NASDAQ-CTXR) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Citius Pharmaceuticals Inc is 22.2%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Citius Pharmaceuticals Inc is 98.2%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,043 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 648.7 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 372.3 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 269.8 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 175.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 159.2 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 127.2 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 102 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 101.9 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.536 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 46.053 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.268 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.639 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 30.107 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.733 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.616 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Overvalued Market Cap 12.702 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.456 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.639 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.564 B